Literature DB >> 21858991

Calculation of electron and isotopes dose point kernels with FLUKA Monte Carlo code for dosimetry in nuclear medicine therapy.

F Botta1, A Mairani, G Battistoni, M Cremonesi, A Di Dia, A Fassò, A Ferrari, M Ferrari, G Paganelli, G Pedroli, M Valente.   

Abstract

PURPOSE: The calculation of patient-specific dose distribution can be achieved by Monte Carlo simulations or by analytical methods. In this study, FLUKA Monte Carlo code has been considered for use in nuclear medicine dosimetry. Up to now, FLUKA has mainly been dedicated to other fields, namely high energy physics, radiation protection, and hadrontherapy. When first employing a Monte Carlo code for nuclear medicine dosimetry, its results concerning electron transport at energies typical of nuclear medicine applications need to be verified. This is commonly achieved by means of calculation of a representative parameter and comparison with reference data. Dose point kernel (DPK), quantifying the energy deposition all around a point isotropic source, is often the one.
METHODS: FLUKA DPKS have been calculated in both water and compact bone for monoenergetic electrons (10-3 MeV) and for beta emitting isotopes commonly used for therapy (89Sr, 90Y, 131I 153Sm, 177Lu, 186Re, and 188Re). Point isotropic sources have been simulated at the center of a water (bone) sphere, and deposed energy has been tallied in concentric shells. FLUKA outcomes have been compared to PENELOPE v.2008 results, calculated in this study as well. Moreover, in case of monoenergetic electrons in water, comparison with the data from the literature (ETRAN, GEANT4, MCNPX) has been done. Maximum percentage differences within 0.8.RCSDA and 0.9.RCSDA for monoenergetic electrons (RCSDA being the continuous slowing down approximation range) and within 0.8.X90 and 0.9.X90 for isotopes (X90 being the radius of the sphere in which 90% of the emitted energy is absorbed) have been computed, together with the average percentage difference within 0.9.RCSDA and 0.9.X90 for electrons and isotopes, respectively.
RESULTS: Concerning monoenergetic electrons, within 0.8.RCSDA (where 90%-97% of the particle energy is deposed), FLUKA and PENELOPE agree mostly within 7%, except for 10 and 20 keV electrons (12% in water, 8.3% in bone). The discrepancies between FLUKA and the other codes are of the same order of magnitude than those observed when comparing the other codes among them, which can be referred to the different simulation algorithms. When considering the beta spectra, discrepancies notably reduce: within 0.9.X90, FLUKA and PENELOPE differ for less than 1% in water and less than 2% in bone with any of the isotopes here considered. Complete data of FLUKA DPKS are given as Supplementary Material as a tool to perform dosimetry by analytical point kernel convolution.
CONCLUSIONS: FLUKA provides reliable results when transporting electrons in the low energy range, proving to be an adequate tool for nuclear medicine dosimetry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21858991     DOI: 10.1118/1.3586038

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

1.  Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images.

Authors:  F Botta; A Mairani; R F Hobbs; A Vergara Gil; M Pacilio; K Parodi; M Cremonesi; M A Coca Pérez; A Di Dia; M Ferrari; F Guerriero; G Battistoni; G Pedroli; G Paganelli; L A Torres Aroche; G Sgouros
Journal:  Phys Med Biol       Date:  2013-11-21       Impact factor: 3.609

2.  Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.

Authors:  Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-03       Impact factor: 9.236

3.  Light propagation along the pericardium meridian at human wrist as evidenced by the optical experiment and Monte Carlo method.

Authors:  Yi-fan Jiang; Chang-shui Chen; Xiao-mei Liu; Rong-ting Liu; Song-hao Liu
Journal:  Chin J Integr Med       Date:  2014-05-26       Impact factor: 1.978

4.  Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.

Authors:  Michael C Kreissl; Heribert Hänscheid; Mario Löhr; Frederik A Verburg; Markus Schiller; Michael Lassmann; Christoph Reiners; Samuel S Samnick; Andreas K Buck; Michael Flentje; Reinhart A Sweeney
Journal:  Radiat Oncol       Date:  2012-06-21       Impact factor: 3.481

5.  Monte Carlo characterization of 169Yb as a high-dose-rate source for brachytherapy application by FLUKA code.

Authors:  Marzieh Anjomrouz; Mahdi Sadeghi; Asghar Haddadi
Journal:  J Appl Clin Med Phys       Date:  2013-07-08       Impact factor: 2.102

6.  Evaluation of dose point kernel rescaling methods for nanoscale dose estimation around gold nanoparticles using Geant4 Monte Carlo simulations.

Authors:  Sandun Jayarathna; Nivedh Manohar; Md Foiez Ahmed; Sunil Krishnan; Sang Hyun Cho
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

7.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.

Authors:  Katarina Sjögreen Gleisner; Nicolas Chouin; Pablo Minguez Gabina; Francesco Cicone; Silvano Gnesin; Caroline Stokke; Mark Konijnenberg; Marta Cremonesi; Frederik A Verburg; Peter Bernhardt; Uta Eberlein; Jonathan Gear
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-14       Impact factor: 10.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.